

Felicia Heidebrecht<sup>1</sup>, Jenny Corless<sup>2</sup>, Mary Bell MacLeod<sup>3</sup>, Lynne Dawkins<sup>1</sup>

<sup>1</sup>London South Bank University, <sup>2</sup>Southwark Drug Services, <sup>3</sup>Camden and Islington NHS Foundation Trust

**Background**

Methadone is used world-wide as a first choice treatment for opioid dependency. However, heroin use in treatment is common, especially for dual users of heroin and crack/cocaine or other stimulants. In addition, intravenous (IV) use increases the risk of health complications, and in an ageing population further chronic conditions such as diabetes, COPD, chronic pain, kidney and liver disease contribute to a deteriorating quality of life.

**Ageing drug users in treatment experience low quality of life**

**Aim**

To explore physical health and drug use in methadone treatment in older people with a history of IV heroin use.

**Methods**

**Participants:** Dual users of heroin and crack cocaine who have ever injected heroin and are currently in methadone treatment at two services in London, UK (age over 40, n=148 for clinical records; n=27 for interviews)

**Data collection:** Secondary analysis based on clinical records and interviews covering the history of drug use, treatment, and physical health.

**Groups compared:** Group 1: currently using heroin, good health  
Group 2: currently using heroin, poor health  
Group 3: heroin abstinent, poor health

**Outcome:** IV-related physical health ('poor health' = IV-related adverse events such as varicose veins, septic arthritis, septicaemia, DVT, pulmonary embolism, endocarditis, stroke)

**Statistical analyses:** Chi<sup>2</sup>, t and Fisher's exact tests, bivariate associations.

**ABBREVIATIONS:**

H - heroin  
SM - smoking  
IV - intravenous  
C - crack cocaine  
MTD - methadone  
CVR - cardiovascular risk(s)  
OST - opiate substitution therapy  
PSI - psychosocial interventions

**NUMBERS**

	Group 1 H use good health	Group 2 H use poor health	Group 3 No H poor health	
<b>Clinical records</b>	N=55	N=62	N=13	
Current H IV	29%	52%	0%	P=0.02
Current C IV	18%	34%	0%	P=0.04
Current C use	98%	97%	77%	
<b>Interviews</b>	N=10	N=10	N=7	
Current H IV	40%	60%	0%	
Current C IV	20%	30%	0%	
Current C use	80%	80%	29%	
Years on MTD	10	15	18	
Years IV on MTD	6	11	13	P=0.01
High Risk IV sites	20%	70%	71%	P=0.04
Switch from IV to SM	90%	50%	29%	P=0.03

**Why are some people injecting crack and/or heroin in good health (group 1) and some people not using heroin at all and only smoking crack in poor health (Group 3)?**

**Why did those in group 3 stop injecting and using heroin but not those in group 2?**

**Is it as simple as switch to SM → good health | HR sites → poor health?**

Switch from IV to SM ↔ good health (OR=0.08, 95% CI: 0.01 – 0.76)  
High risk IV sites ↔ poor health (OR=9.6, 95% CI: 1.5 – 62.2)

**LESSONS - all interviews**

- motivation for treatment: reducing/controlling drug use more often than abstinence
- Switch to neck/groin and DVT/stroke after first MTD treatment or on MTD
- Group 1 (H use, good health): reasons for IV stop: social/improve health; little groin/neck IV; MTD mainly <60 mg/day; less frequent IV use than groups 2 & 3
- Group 2 and 3 (poor health): IV stop after health scare (DVT, OD), or no veins at a high risk site regardless of MTD dose
- reverse transition from IV to smoking before compromised health more often on MTD <60 mg/day

Need for new treatment discourse away from abstinence (-only)?

MTD does not always prevent transition to high risk IV and deterioration of health

IV stop before health compromised

IV stop only after health compromised

could lower MTD dose + PSI help achieve a reverse transition?

How else does MTD help people use safer (use only one instead of both H and C)?

Some people want to continue enjoying H

Some people enjoy the C but not the 'come down'

On high MTD dose there's no point in using H without the C.

If I have MTD I feel more comfortable using only the C, before I had to have H to come down


If you smoke C on MTD you only feel the C and not the MTD, I always need H to come down

Would a lower MTD dose help to use H only?

Would a higher MTD dose and/or PSI help to use only C?

**STORIES**

	Group 1 H use good health	Group 2 H use poor health	Group 3 No H poor health
<b>Case studies</b>	SAM	PAT	CHRIS
High Risk IV sites	YES	YES	YES
Switch from IV to SM	YES	YES	YES
Age	46y	46y	54y
Years of drug use	25	31	37
Years of IV drug use	19	31	20
Years on MTD	12	29	18
Years IV on MTD	11	27	15
MTD dose	55	100	100
IV-rel health problem	NO	DVT	stroke
Reason to stop IV	to improve health	Kidney Disease	No veins anywhere
Reason to stop SM	NO	NO	COPD



**QUESTIONS & COMMENTS?**

felicias.research@gmx.de

@lifeinmymind3

FeliciaHeidebrecht

www.lifeinmymind.net

**Discussion**

**MTD is a harm reduction intervention but IS THIS ENOUGH?**


Some people access methadone treatment to reduce rather than stop drug use. Routinely collected clinical data give only a partial view on long-term outcomes of IV users in treatment. The history of injecting behaviour, health, social life and users' own narratives are necessary to understand poor outcomes in older age, and find ways to reduce health deterioration.

**MTD could be as well a safer drug use intervention and could further improve drug users' health if (prescribing) services would:**

- consider equally benefits and risks of drug use
- create space to talk openly about the true motivation and listen to people's choices
- talk about long-term health deterioration due to drug use but offer OST and PSI aimed at safer use on top if this is person's choice
- not limit counselling for broader life challenges to only those who are 'stable' on OST but offer it in Drug Consumption Rooms, Needle Exchanges and to those using on top of OST if they want it
- review risks of drug use, general health and safer use advice when people age

**LESSONS - Chris**

Harm Reduction aims for BALANCE. What went wrong with Chris?



**Risks and problems increase with ageing!**

Early signs that MTD didn't work for abstinence and future severe cardiovascular problems could have been recognized earlier by services:

- 15 years of IV use on MTD; start of IV in the neck while on MTD

- early signs of poor CV health/CV risks: tobacco smoker from very young age, poor injecting technique, veins collapsing quickly, pre-metabolic syndrome

**What else could have the treatment service?**

- earlier switch IV → SM? (but poor CV health from young age, so was SM ever lower risk than IV for Chris?)
- Lower or higher MTD dose and PSI aimed at lower frequency of drug use on top?
- safer injecting advice along with MTD prescription?
- education on ALL CVR factors e.g. diet, tobacco/heroin/crack smoking, exercise, injecting technique...?
- broader behaviour change support to reduce any possible CV risk (diet, exercise...)?
- emotional support/counselling despite drug use?
- Could such interventions have prevented or at least delayed the COPD (and the stroke?)
- Further COPD exacerbations and diabetes could possibly still be prevented!

**Moving forward?**

Limitations of this study: retrospective, recollection bias, regional sample, low numbers

- more research
- Larger-scale data (e.g. routinely collecting data on IV-related health, changes in injecting sites and other relevant parameters during MTD/OST treatment at national and European level)
- design and trial of PSI aimed at safer and controlled drug use, and optimization of MTD dose for safer on top use
- change of political, social and health care discourse!

The authors thank the staff in Southwark and Waltham Forest drug services for help with recruitment, Jean Pender for additional support with the study and all interviewed drug users for their time and willingness to share their views and experience.

The authors declare no conflicts of interest. The study was approved by the Ethics Committee of the London South Bank University and was partially funded by Lifeline Project.